Ophthalmopathy
18
3
3
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.6%
1 terminated out of 18 trials
90.9%
+4.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (18)
Assessment of the Ocular Microbiome in Health and Disease
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery
Effect Of Reusing the Operative Supplies On Cataract Surgery and Climate Change
Evaluating Medium-chain Triglycerides as a Temporary Intraocular Tamponading Agent for Retinal Detachment
Refractive Transepithelial Photo-keratectomy (T-PKR) in High Myopia
Autologous Blood for Full-thickness Macular Hole
Single Superior ILM/ERM Flap for the FTMH.
Phaco-Trabeculotomy Vs Phaco-Trabeculectomy
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
Ocular Manifestations of Inflammatory Bowel Disease
Assessment of COVID-19 in Tearfilm
Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
Validation of the Utility of Ophthalmology Intelligent Diagnostic System
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Validation of the Utility of an Intelligent Visual Acuity Diagnostic System for Children
Artificial Intelligence Screening on Patients With Primary Angle Closure Glaucoma